Boston Scientific upgraded by Mizuho with a new price target
$BSX
Medical/Dental Instruments
Health Care
Mizuho upgraded Boston Scientific from Neutral to Buy and set a new price target of $80.00 from $65.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $118.00 | Outperform | Leerink Partners |
| 4/16/2025 | $113.00 | Hold → Buy | Needham |
| 1/10/2025 | $108.00 | Hold → Buy | Deutsche Bank |
| 10/18/2024 | Buy → Hold | Needham | |
| 5/30/2024 | $90.00 | Buy | Goldman |
| 2/1/2024 | $65.00 → $80.00 | Neutral → Buy | Mizuho |
| 7/19/2023 | $59.00 | Outperform | Robert W. Baird |
| 6/30/2023 | $64.00 | Buy | CL King |
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of
MARLBOROUGH, Mass., May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in two upcoming investor conferences in May. On May 13, 2025, Dan Brennan, executive vice president and chief financial officer, and Joe Fitzgerald, executive vice president and group president, Cardiology, will participate in a 30-minute question-and-answer session with the host analyst at Bank of America's 2025 Health Care Conference. The session will begin at approximately 8:00 a.m. PT / 11:00 a.m. ET. On May 28, 2025, Mike Mahoney, chairman and chief executive officer,
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025. "I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific," said Mike Mahoney, chairman and chief executi
For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide